<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719885</url>
  </required_header>
  <id_info>
    <org_study_id>830076</org_study_id>
    <nct_id>NCT03719885</nct_id>
  </id_info>
  <brief_title>TrueTear in Sjogren's Disease Patients</brief_title>
  <official_title>Prospective Controlled Study of Intranasal Tear Neurostimulation for Sjogrens Patients With Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate acute tear production produced by the intranasal&#xD;
      tear neurostimulator in participants with Sjögrens syndrome and aqueous tear deficiency. Our&#xD;
      primary goal is to evaluate whether Sjögrens patients respond to this intervention and&#xD;
      whether there is a baseline tear production level below which these patients do not respond.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Schirmer Testing</measure>
    <time_frame>Immediately following the procedure (ie immediately following use of the device)</time_frame>
    <description>Tear production measured immediately following intranasal tear neurostimulation. For this measurement, Schirmer strips (small strips of paper with measurements on them) are placed in the corner of each eye. The amount of wetting of the Schirmer strips is measured in millimeters. Wetting of less than 5 mm is indicative of deficient tear production.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Changes in Visual Acuity</measure>
    <time_frame>Immediately following the procedure (ie immediately following use of the device)</time_frame>
    <description>Clinically significant change in Best corrected visual acuity (BCVA)- this measurement was taken to determine if a significant change in BCVA was noted for participants. If a clinically significant change was noted (greater or equal to 2 lines of vision) then a subject would be listed in the data table below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Significant Changes in Slit Lamp Exam</measure>
    <time_frame>Immediately following the procedure (ie immediately following use of the device)</time_frame>
    <description>Clinically significant changes in slit lamp examination . Subjects who experienced clinically significant changes would be represented in the data table below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Immediately following the procedure (ie immediately following use of the device)</time_frame>
    <description>Pain, headache, nosebleed, etc felt to be associated with use of the device</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TrueTear Intranasal Tear Neurostimulator</intervention_name>
    <description>This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with Sjögren's syndrome based on American-European Consensus Group (AECG)&#xD;
             American College of Rheumatology (ACR), or American College of Rheumatology/European&#xD;
             League Against Rheumatism (ACR/EULAR) criteria&#xD;
&#xD;
          -  Baseline Schirmer score (with topical anesthesia) of ≤10 mm/5 min and retest value&#xD;
             (during nasal stimulation with cotton swab) of at least 4 mm/5min higher than baseline&#xD;
             value&#xD;
&#xD;
          -  Baseline Ocular Surface Disease Index® (OSDI) total score ≥13&#xD;
&#xD;
          -  Age greater than or equal to 22 years old&#xD;
&#xD;
          -  Able to complete questionnaires independently&#xD;
&#xD;
          -  Willing to sign the informed consent and deemed capable of complying with the&#xD;
             requirements of the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any topical ophthalmic medication, including artificial tears, within 4 hours&#xD;
             of either visit&#xD;
&#xD;
          -  Chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the&#xD;
             opinion of the investigator, may lead to clinically significant increased bleeding&#xD;
&#xD;
          -  Use of systemic anticoagulants&#xD;
&#xD;
          -  Nasal or sinus surgery including nasal cautery or significant trauma&#xD;
&#xD;
          -  Severely deviated septum&#xD;
&#xD;
          -  Cardiac demand pacemaker, implanted defibrillator or other implanted electronic device&#xD;
&#xD;
          -  Have an active implanted metallic or active implanted electronic device in the head, a&#xD;
             cardiac demand pacemaker, or an implanted defibrillator&#xD;
&#xD;
          -  Known hypersensitivity to any of the procedural agents or materials in the study&#xD;
             device that contact the nasal mucosa&#xD;
&#xD;
          -  Corneal transplant in either or both eyes&#xD;
&#xD;
          -  Participation in any clinical trial within 30 days of the Screening Visit&#xD;
&#xD;
          -  A woman who is pregnant, planning a pregnancy, or nursing at the Screening Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giacomina Massaro-Giordano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scheie Eye Insitute, University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scheie Eye Institute, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <results_first_submitted>June 11, 2020</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 25, 2020</results_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03719885/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03719885/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Group</title>
          <description>The participants recruited for this study were those who were 22 years or older, had a clinical diagnosis of Sjogren's Syndrome (SS), and produced 10 mm. or less of tears over the course of 5 minutes (measured using Schirmer strips). They also had to have an OSDI score ≥13.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Same as assignment in Participant Flow</population>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>The participants recruited for this study were those who had a clinical diagnosis of Sjogren's Syndrome (SS) and produced 10 mm. or less of tears over the course of 5 minutes (measured using Schirmer strips).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Year of Sjogren's diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prior to 2000</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2000 - 2010</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>After 2010</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OSDI Score</title>
          <description>[low of 0, high of 100] Higher score means more affected by dry eye symptoms, lower score means less affected by dry eye symptoms- OSDI score defined the ocular surface as normal (0-12 points) or as having mild (13-22 points), moderate (23-32 points), or severe (33-100 points) disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Schirmer Testing</title>
        <description>Tear production measured immediately following intranasal tear neurostimulation. For this measurement, Schirmer strips (small strips of paper with measurements on them) are placed in the corner of each eye. The amount of wetting of the Schirmer strips is measured in millimeters. Wetting of less than 5 mm is indicative of deficient tear production.</description>
        <time_frame>Immediately following the procedure (ie immediately following use of the device)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>TrueTear Intranasal Tear Neurostimulator: This study will evaluate the difference between active and control applications in tear production during active stimulation as measured by Schirmer testing</description>
          </group>
        </group_list>
        <measure>
          <title>Schirmer Testing</title>
          <description>Tear production measured immediately following intranasal tear neurostimulation. For this measurement, Schirmer strips (small strips of paper with measurements on them) are placed in the corner of each eye. The amount of wetting of the Schirmer strips is measured in millimeters. Wetting of less than 5 mm is indicative of deficient tear production.</description>
          <units>mm.</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cotton Swab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extranasal Application</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intranasal Application</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Changes in Visual Acuity</title>
        <description>Clinically significant change in Best corrected visual acuity (BCVA)- this measurement was taken to determine if a significant change in BCVA was noted for participants. If a clinically significant change was noted (greater or equal to 2 lines of vision) then a subject would be listed in the data table below.</description>
        <time_frame>Immediately following the procedure (ie immediately following use of the device)</time_frame>
        <population>Participants' eyes were examined pre and post active application to confirm that the device did not cause any changes to the participant's vision. A serious change in vision would have been reported as an adverse event</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>TrueTear Intranasal Tear Neurostimulator: This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Changes in Visual Acuity</title>
          <description>Clinically significant change in Best corrected visual acuity (BCVA)- this measurement was taken to determine if a significant change in BCVA was noted for participants. If a clinically significant change was noted (greater or equal to 2 lines of vision) then a subject would be listed in the data table below.</description>
          <population>Participants' eyes were examined pre and post active application to confirm that the device did not cause any changes to the participant's vision. A serious change in vision would have been reported as an adverse event</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Significant Changes in Slit Lamp Exam</title>
        <description>Clinically significant changes in slit lamp examination . Subjects who experienced clinically significant changes would be represented in the data table below.</description>
        <time_frame>Immediately following the procedure (ie immediately following use of the device)</time_frame>
        <population>Eyes were examined pre and post active application to confirm that the device did not cause any changes to the physical structure or appearance of the eyes</population>
        <group_list>
          <group group_id="O1">
            <title>Intervetion</title>
            <description>TrueTear Intranasal Tear Neurostimulator: This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Changes in Slit Lamp Exam</title>
          <description>Clinically significant changes in slit lamp examination . Subjects who experienced clinically significant changes would be represented in the data table below.</description>
          <population>Eyes were examined pre and post active application to confirm that the device did not cause any changes to the physical structure or appearance of the eyes</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events</title>
        <description>Pain, headache, nosebleed, etc felt to be associated with use of the device</description>
        <time_frame>Immediately following the procedure (ie immediately following use of the device)</time_frame>
        <population>All participants who used the device were observed for any adverse events</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>TrueTear Intranasal Tear Neurostimulator: This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Pain, headache, nosebleed, etc felt to be associated with use of the device</description>
          <population>All participants who used the device were observed for any adverse events</population>
          <units>occurance of adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the duration of the study (from the time the patient was enrolled in the study until they completed visit 2). We also provided patients with our contact information, in case they experienced any adverse events in the days following visit 2.</time_frame>
      <desc>The adverse event data was collected immediately following the event. The subject was also called a week later to ensure that the issue had resolved.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>The participants recruited for this study were those who had a clinical diagnosis of Sjogren's Syndrome (SS) and produced 10 mm. or less of tears over the course of 5 minutes (measured using Schirmer strips).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Small conjunctival hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Research Coordinator</name_or_title>
      <organization>Penn Medicine</organization>
      <phone>215-662-9393</phone>
      <email>jonathan.lilley@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

